 |
|
|
| |
All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1b Infection: Phase 3 HALLMARK-DUAL Study Results
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng C-Y, Chang T-T, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu C-J, Sievert W, Bronowicki J-P, Thabut D, Lee Y-J, Kao J-H, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S, and the HALLMARK-DUAL Study Team
|
| |
|
|
|
|
|
